COCI Business Event Draws 240+ Attendees, Far Surpassing Expectations

St. Maarten Medical Center (SMMC) has recorded Cg. 10.1 million in unpaid patient bills so far in 2025, representing a significant financial burden for the island's primary public hospital located in Cay Hill. The mounting debt reflects an ongoing challenge faced by SMMC, where patients either lack adequate health insurance or fail to settle their accounts after receiving care. This level of uncollected revenue threatens the hospital's operational budget and its ability to sustain quality healthcare services for residents and visitors alike. SMMC is St. Maarten's main medical facility, making its financial stability a matter of direct public concern. The scale of the shortfall underscores broader systemic issues around healthcare financing and insurance coverage on the island. If left unaddressed, the accumulating debt could impact staffing, equipment procurement, and the range of services the hospital is able to offer.

The St. Maarten Medical Center (SMMC) recorded a surplus of Cg 11.8 million in 2025, reflecting a significant improvement in the hospital's financial position. Total revenue for the year climbed to Cg 138.9 million, signaling strong operational performance for the island's primary healthcare facility. The figures suggest continued recovery and growth following years of financial and infrastructural challenges, including damage sustained during Hurricane Irma in 2017. A surplus of this scale gives the medical center greater capacity to invest in equipment, staffing, and services for the population of St. Maarten. The results are seen as a positive indicator for healthcare sustainability on the island, where access to quality medical services remains a critical concern. No specific breakdown of revenue sources or expenditure categories was provided in the excerpt, but the headline figures point to a financially healthier institution heading into the near term.

Danish pharmaceutical giant Novo Nordisk has filed a lawsuit against U.S.-based rival Eli Lilly, accusing the company of false and deceptive advertising related to its GLP-1 weight-loss and diabetes medications. The legal action centers on claims that Eli Lilly made misleading comparisons or statements about its GLP-1 drugs — a class that includes blockbuster obesity treatments like semaglutide and tirzepatide. Both companies are major competitors in the rapidly growing GLP-1 market, which has exploded in value as demand for weight-loss medications surges globally. Novo Nordisk, maker of Ozempic and Wegovy, alleges that Eli Lilly's advertising misrepresents the efficacy or safety profile of its competing products. The lawsuit reflects the intensifying commercial rivalry between the two dominant players in what has become one of the most lucrative pharmaceutical sectors in recent history. No immediate court rulings have been reported, and Eli Lilly has not yet issued a detailed public response to the claims.